Gursah Kats-Ugurlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gursah Kats-Ugurlu has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Boudewijn van Etten
Department of Surgery University of Groningen, University Medical Center Groningen Groningen The Netherlands
14 shared publications - Anne M. van der Waaij
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 1
13 shared publications - Dominic J. Robinson
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
13 shared publications - Frederieke A. Dijkstra
Department of Surgery University of Groningen, University Medical Center Groningen Groningen The Netherlands
13 shared publications - Gert Jan Meersma
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 1
13 shared publications - Iris Schmidt
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 1
13 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8) , e70309
Optimising Expert Pathology Referral in Barrett's Oesophagus Dysplasia Through p53‐Guided Triage: A Nationwide Real‐World Cohort Study
Background: Histopathological interpretation of Barrett's oesophagus‐associated dysplasia remains variable, and although guidelines recommend expert pathology review, specialist capacity is increasingly constrained. We assessed the real‐world diagnostic impact of national expert review and tested whether p53‐IHC identifies subgroups in which review is high‐ or low‐yield. Methods: The Dutch Oesophageal Pathology Panel reviewed consecutive BE cases submitted from 39 hospitals (2015–2024). Digitised haematoxylin and eosin‐stained and p53‐IHC slides were assessed by experienced gastrointestinal pathologists. Panel diagnoses required ≥ 75% agreement or consensus meeting review. Referring and panel diagnoses were compared at the patient level, with biopsy‐level analyses assessing diagnostic shifts according to referring‐centre p53‐IHC status (wild‐type, aberrant or equivocal). Results: The cohort included 1146 consecutive patients and 2187 biopsy levels, each assessed by a median of 12 panel pathologists. Expert review changed 46.9% of referring diagnoses (downgrading 24.7% and upgrading 22.2%). Indefinite for dysplasia (IND) was the most unstable diagnostic category, with 73.4% of cases reclassified. Among 1731 biopsy levels with reported p53‐IHC at referral, p53‐IHC strongly stratified review yield. Low‐grade or high‐grade dysplasia (LGD/HGD) with aberrant p53‐IHC was confirmed in 91.7% of biopsy levels. In contrast, LGD/HGD with wild‐type or equivocal p53‐IHC showed substantially higher downgrade rates (53.6% and 32.8%), with odds ratios for diagnostic adjustment of 12.7 (95% CI: 8.2–19.7) and 5.4 (95% CI: 2.9–10.0) versus aberrant p53‐IHC. Conclusion: Expert review substantially altered BE dysplasia diagnoses, supporting current guideline recommendations. P53‐IHC markedly stratified review yield: IND and dysplasia with wild‐type or equivocal p53‐IHC remain high‐priority categories, whereas aberrant p53‐IHC dysplasia was rarely reclassified. A p53‐guided triage strategy could help optimise the use of expert pathology capacity, but prospective validation is needed before clinical implementation.
- 26 October 2026
- Published by Wiley in United European Gastroenterology Journal
- Vol. 14 (8) , e70309
Open AccessOptimising Expert Pathology Referral in Barrett's Oesophagus Dysplasia Through p53‐Guided Triage: A Nationwide Real‐World Cohort Study
Background: Histopathological interpretation of Barrett's oesophagus‐associated dysplasia remains variable, and although guidelines recommend expert pathology review, specialist capacity is increasingly constrained. We assessed the real‐world diagnostic impact of national expert review and tested whether p53‐IHC identifies subgroups in which review is high‐ or low‐yield. Methods: The Dutch Oesophageal Pathology Panel reviewed consecutive BE cases submitted from 39 hospitals (2015–2024). Digitised haematoxylin and eosin‐stained and p53‐IHC slides were assessed by experienced gastrointestinal pathologists. Panel diagnoses required ≥ 75% agreement or consensus meeting review. Referring and panel diagnoses were compared at the patient level, with biopsy‐level analyses assessing diagnostic shifts according to referring‐centre p53‐IHC status (wild‐type, aberrant or equivocal). Results: The cohort included 1146 consecutive patients and 2187 biopsy levels, each assessed by a median of 12 panel pathologists. Expert review changed 46.9% of referring diagnoses (downgrading 24.7% and upgrading 22.2%). Indefinite for dysplasia (IND) was the most unstable diagnostic category, with 73.4% of cases reclassified. Among 1731 biopsy levels with reported p53‐IHC at referral, p53‐IHC strongly stratified review yield. Low‐grade or high‐grade dysplasia (LGD/HGD) with aberrant p53‐IHC was confirmed in 91.7% of biopsy levels. In contrast, LGD/HGD with wild‐type or equivocal p53‐IHC showed substantially higher downgrade rates (53.6% and 32.8%), with odds ratios for diagnostic adjustment of 12.7 (95% CI: 8.2–19.7) and 5.4 (95% CI: 2.9–10.0) versus aberrant p53‐IHC. Conclusion: Expert review substantially altered BE dysplasia diagnoses, supporting current guideline recommendations. P53‐IHC markedly stratified review yield: IND and dysplasia with wild‐type or equivocal p53‐IHC remain high‐priority categories, whereas aberrant p53‐IHC dysplasia was rarely reclassified. A p53‐guided triage strategy could help optimise the use of expert pathology capacity, but prospective validation is needed before clinical implementation.
- Open Access
- 19 June 2026
- Published by Wiley in Histopathology
- Vol. 89 (4) , 614-623
Diagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP )
Introduction: Evidence supporting the use of p53 immunohistochemistry (p53‐IHC) in Barrett's oesophagus (BE) is largely based on selected series, limiting generalizability. This study evaluates p53‐IHC in a nationwide, real‐world BE‐cohort within a universal healthcare system, assessing concordance with referring hospitals, interobserver agreement (IOA) and its impact on routine diagnostic decisions. Methods: Revision cases submitted to the Dutch Esophageal Pathology Panel (DEPP) were assessed by trained and experienced pathologists for haematoxylin and eosin (H&E)‐based classification (Vienna classification), p53‐IHC patterns (wild‐type, overexpression, double clone, null mutation and equivocal) and combined H&E/p53‐IHC review. Concordance between referring hospitals and the expert panel (Cohen's kappa) and IOA among panel pathologists (Fleiss' kappa) were assessed, along with the impact of p53‐IHC on diagnostic reclassification. Results: A total of 1,146 consecutive patient consultation cases (1,704 biopsy levels) were included, with a median of 12 DEPP pathologist assessments per biopsy. Overall concordance of p53 assessment between referring hospitals and the expert panel was moderate‐to‐substantial ( κ = 0.61, 95% CI 0.58–0.64), with 24.2% of p53‐IHC assessments reclassified. IOA among 13 pathologists assessing 316 endoscopic biopsies was substantial ( κ = 0.65, 95% CI 0.61–0.69). Ancillary p53‐IHC influenced pathologists' decisions across biopsy levels. For non‐dysplastic (NDBE) biopsies, aberrant p53‐IHC prompted reclassification to indefinite for dysplasia (IND, 9.2%) or low‐grade dysplasia (LGD, 4.8%). For IND biopsies, p53‐IHC shifted diagnoses toward NDBE (17.0%) or LGD (37.1%). Conclusion/discussion: p53‐IHC interpretation is reliable, reproducible and clinically meaningful in BE diagnostics when standardized criteria are applied. These findings support broader use of p53‐IHC in routine practice and incorporation of assessment criteria into guidelines.
- 19 June 2026
- Published by Wiley in Histopathology
- Vol. 89 (4) , 614-623
Open AccessDiagnostic impact and reproducibility of p53 immunohistochemistry in Barrett's oesophagus: results of the Dutch Esophageal Pathology Panel ( DEPP )
Introduction: Evidence supporting the use of p53 immunohistochemistry (p53‐IHC) in Barrett's oesophagus (BE) is largely based on selected series, limiting generalizability. This study evaluates p53‐IHC in a nationwide, real‐world BE‐cohort within a universal healthcare system, assessing concordance with referring hospitals, interobserver agreement (IOA) and its impact on routine diagnostic decisions. Methods: Revision cases submitted to the Dutch Esophageal Pathology Panel (DEPP) were assessed by trained and experienced pathologists for haematoxylin and eosin (H&E)‐based classification (Vienna classification), p53‐IHC patterns (wild‐type, overexpression, double clone, null mutation and equivocal) and combined H&E/p53‐IHC review. Concordance between referring hospitals and the expert panel (Cohen's kappa) and IOA among panel pathologists (Fleiss' kappa) were assessed, along with the impact of p53‐IHC on diagnostic reclassification. Results: A total of 1,146 consecutive patient consultation cases (1,704 biopsy levels) were included, with a median of 12 DEPP pathologist assessments per biopsy. Overall concordance of p53 assessment between referring hospitals and the expert panel was moderate‐to‐substantial ( κ = 0.61, 95% CI 0.58–0.64), with 24.2% of p53‐IHC assessments reclassified. IOA among 13 pathologists assessing 316 endoscopic biopsies was substantial ( κ = 0.65, 95% CI 0.61–0.69). Ancillary p53‐IHC influenced pathologists' decisions across biopsy levels. For non‐dysplastic (NDBE) biopsies, aberrant p53‐IHC prompted reclassification to indefinite for dysplasia (IND, 9.2%) or low‐grade dysplasia (LGD, 4.8%). For IND biopsies, p53‐IHC shifted diagnoses toward NDBE (17.0%) or LGD (37.1%). Conclusion/discussion: p53‐IHC interpretation is reliable, reproducible and clinically meaningful in BE diagnostics when standardized criteria are applied. These findings support broader use of p53‐IHC in routine practice and incorporation of assessment criteria into guidelines.
- Open Access
- 25 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110397
Feasibility of optical stereotactic navigation for rectosigmoid cancer with deep learning-supported 3D modelling
- 25 August 2025
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (11) , 110397
Open AccessFeasibility of optical stereotactic navigation for rectosigmoid cancer with deep learning-supported 3D modelling
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Purpose:The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT.Experimental Design:Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties—specifically, the absorption and reduced scattering coefficients—were combined into a new parameter called omega.Results:First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86–3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue.Conclusions:Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Purpose:The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT.Experimental Design:Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties—specifically, the absorption and reduced scattering coefficients—were combined into a new parameter called omega.Results:First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86–3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue.Conclusions:Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Material S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Description of resection specimen and determination of optical properties
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Description of resection specimen and determination of optical properties
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression